血清RDW、MMP-9联合GOS评分对动脉瘤蛛网膜下腔出血介入治疗预后的预测价值

目的检测血清红细胞分布宽度（RDW）、基质金属蛋白酶9（MMP-9）联合格拉斯哥预后量表（GOS）评分对动脉瘤蛛网膜下腔出血（aSAH）介入治疗预后的预测价值。方法回顾性分析108例行支架辅助动脉瘤栓塞术治疗的aSAH患者的临床资料，随访1年后获取患者基线资料，采用多重线性回归分析、Logistic回归分析各指标与预后的相关性，ROC曲线分析RDW、MMP-9联合GOS评分对预后的预测价值。结果年龄、RDW、MMP-9是影响GOS评分的独立相关因素（P<0.05）。RDW、MMP-9可鉴别诊断aSAH患者GOS评分≤3分/>3分（P<0.05）。结论RDW、MMP-9与aSAH介入患者预后评分指标GOS评分相关，通过检测RDW、MMP-9可用于辅助判断患者预后，对指导早期治疗具有积极作用。

Abstract： Objective To investigate the value of serum red blood cell distribution width(RDW) and matrix metalloproteinase-9(MMP-9) combined with Glasgow outcome scale(GOS) score in predicting the prognosis of aneurysmal subarachnoid hemorrhage(aSAH) after interventional therapy. Methods The clinical data of 108 patients with aSAH who had been treated with stent assisted aneurysm embolization were analyzed retrospectively. Patients were followed up 1 year, then various data were collected. Multiple linear regression analysis and Logistic regression analysis were used to analyze the correlation between each index and prognosis. ROC regression curve was used to detect the predictive value of RDW, MMP-9 combined with GOS score on prognosis. Results Age, RDW, and MMP-9 were independent related factors that affect GOS score(P<0.05). RDW and MMP-9 could differentiate and diagnose the GOS score of aSAH patients ≤3 or>3(P<0.05). Conclusions RDW and MMP-9 are related to the GOS score of aSAH patients with intervention therapy, so the detection of RDW and MMP-9 can be used to judge the prognosis and guide early treatment of patients.